NAD Precursors Billing & Prior-Auth Playbook

What Is the NAD Precursors Drug Class?

NAD precursors are compounds that the body converts into nicotinamide adenine dinucleotide (NAD+), a coenzyme central to mitochondrial oxidative phosphorylation, DNA repair via PARP-1 and SIRT1 pathways, and cellular energy transfer. The class includes niacin (vitamin B3), nicotinamide (NAM), nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and intravenous NAD+ itself.

Clinically, the interest in this class stems from human data showing that circulating NAD+ levels decline roughly 50% between ages 40 and 60. A 2023 review in Ageing Research Reviews (N=12 controlled trials) found that oral NR and NMN consistently raised whole-blood NAD+ by 1.5- to 2.8-fold over 2-to-12 weeks.

The Four Clinically Relevant Precursors

Niacin (nicotinic acid). The oldest and cheapest route. Prescription-grade extended-release niacin (Niaspan) is FDA-approved for dyslipidemia, meaning it carries an NDC and can, in narrow cases, be billed conventionally. The flush side-effect profile limits tolerability above 1,500 mg/day.

Nicotinamide (NAM). Over-the-counter, low cost. Raises NAD+ but also inhibits SIRT1 at high doses, which may blunt some of the benefits seen with NR and NMN. One 2022 randomized trial (N=30) in Nutrients showed NAM 500 mg/day raised blood NAD+ by 1.3-fold but did not improve mitochondrial respiration markers.

NR and NMN. These are the primary commercially available "longevity-focused" precursors. NR is available as Tru Niagen (ChromaDex), a finished dietary supplement. NMN lost its dietary-supplement designation after FDA's 2022 enforcement discretion guidance, placing it in a regulatory gray zone that directly affects how you document and dispense it.

IV NAD+. Administered parenterally, 250-1,000 mg per session, typically over 2-4 hours. Requires a 503A/503B compounding pharmacy for the sterile preparation and carries the most complex billing workflow of the class.

Why NAD+ Declines With Age

The decline is driven by reduced biosynthesis from tryptophan, increased consumption by CD38 (an NADase that rises with inflammatory signaling), and decreased NAMPT activity (the rate-limiting enzyme in the salvage pathway). A 2022 paper in Nature Aging identified CD38-expressing macrophages as a primary driver of the age-related NAD+ decline in mouse models, with partial translational evidence in human adipose tissue.

Regulatory Status: What Your Prescribing Authority Actually Covers

The single biggest billing error practitioners make is treating NAD precursors like a compounded hormone. They are not the same regulatory category, and conflating them creates audit risk.

FDA Enforcement and the 2022 NMN Guidance

In November 2022, FDA issued a response to a citizen petition confirming that NMN had been authorized for investigation as a new drug before it was marketed as a supplement. Under 21 U.S.C. § 321(ff)(3)(B)(ii), this disqualifies NMN from the dietary-supplement definition. The FDA's published response is available at the FDA website. Practically, this means retail NMN sales are technically unlawful, but FDA has not issued warning letters as of early 2025, and compounded NMN remains available through 503A pharmacies for individual patients.

NR does not share this restriction. As a substance marketed as a supplement before any IND authorization, NR retains its supplement status and can be recommended by clinicians without a prescription, though it cannot be billed as a prescription drug.

Compounding Pharmacy Requirements for IV NAD+

Sterile IV NAD+ must come from a 503A (patient-specific) or 503B (outsourcing facility) pharmacy. FDA's guidance on 503A and 503B distinctions is outlined at the FDA compounding resource page. Key points for billing:

• The compounding pharmacy assigns an NDC or uses a bulk-drug NDC placeholder.
• The drug itself is typically not billable to insurance. The administration procedure is potentially billable.
• The pharmacy's 503B status matters for hospitals and infusion centers that need to bill the drug component under a facility claim.

Billing Architecture for NAD Precursor Services

There is no CPT code specific to NAD+ infusions. Billing flows through a combination of evaluation-and-management codes, infusion administration codes, and direct-pay or membership structures.

E&M Visit Coding

Every NAD precursor service should start with a documented medical visit. For new patients, a 99205 (new patient, high complexity) is defensible when:

1. You review prior metabolic labs, medication history, and cardiovascular risk.
2. You order baseline NAD+ levels (Jinfiniti's intracellular NAD+ test is the most widely used clinical reference).
3. You document the specific indication or wellness goal in clinical terms.

For established patients returning for repeat IV sessions, a 99214 or 99215 is appropriate depending on complexity. Do not bill a separate E&M on the same day as an infusion unless it is a distinct, separately documented service with a modifier -25.

IV Infusion Administration Codes

IV NAD+ administration uses the standard therapeutic infusion hierarchy:

• 96365: IV infusion, initial, up to 1 hour.
• 96366: Each additional hour (add-on code, requires 96365 as base).
• 96367 / 96368: Concurrent or sequential infusion if you are co-infusing vitamins (e.g., a Myers' cocktail alongside NAD+).

A 500 mg NAD+ infusion typically runs 2.5-3 hours at standard titration rates to minimize the flushing, chest tightness, and nausea that occur with rapid infusion. Bill 96365 plus two units of 96366 for a 3-hour session.

HealthRX NAD+ Infusion Billing Decision Framework:

| Scenario | Codes | Notes | |---|---|---| | New patient consult + first IV NAD+ | 99205-25, 96365, 96366 x2 | Modifier -25 on E&M required | | Established patient, IV only | 96365, 96366 x2 | No separate E&M unless distinct problem addressed | | Oral NMN/NR follow-up visit only | 99214 | No infusion codes | | IV NAD+ + concurrent Myers' cocktail | 96365, 96366, 96367 | Confirm concurrent vs. Sequential per payer rule | | Initial alcohol-use disorder adjunct protocol | 99205-25, 96365, 96366 x3-4, H0004 | H0004 for substance abuse services if applicable |

Direct-Pay and Membership Structures

Because commercial payers deny NAD+ infusion drug costs, most practices use one of three revenue models:

1. Flat-session fee. A single cash price covering drug, supplies, and nursing time. Typical market range: $200-$600 per session depending on dose and geography.
2. Membership bundles. Monthly membership covering 2-4 infusions plus oral supplementation. Helps with patient retention and predictable revenue.
3. HSA/FSA billing. Patients with health savings accounts may reimburse cash-pay infusion services if the provider issues a superbill with ICD-10 codes documenting a medical purpose. A diagnosis of E52 (niacin deficiency), confirmed by lab, is the strongest anchor. G93.3 (postviral fatigue/ME-CFS adjacent diagnoses) is used by some practitioners for post-COVID NAD depletion protocols, though documentation must be airtight.

Prior Authorization: What to Expect and How to Document

For the minority of practitioners who attempt insurance billing of any NAD-adjacent service, understanding the prior-auth field prevents wasted administrative hours.

Payer Positions

Commercial payers including UnitedHealthcare, Aetna, and BCBS currently have no positive coverage policies for NMN, NR, or IV NAD+. The absence of a Local Coverage Determination (LCD) that supports these agents means any claim goes to a medical-necessity review against an LCD that does not recognize the indication.

Medicare and Medicaid follow the same pattern. CMS has not issued a National Coverage Determination for NAD precursors, so MAC contractors default to non-coverage.

The one narrow exception: extended-release niacin prescribed for a documented dyslipidemia with a valid ICD-10 of E78.5 (hyperlipidemia, unspecified) or E78.00 (pure hypercholesterolemia) may process through a standard pharmacy benefit. AHA/ACC guidelines on dyslipidemia management confirm niacin as a secondary agent in select patients intolerant of statins.

How to Write a Defensible Medical Necessity Letter

When a patient wants to use insurance or an FSA and you need to submit documentation:

• Lead with a quantified lab finding. "Patient's intracellular NAD+ level measured 18.4 micromolar (Jinfiniti reference range 25-50 micromolar), consistent with clinically significant NAD+ deficiency."
• Anchor to an ICD-10 code. E52 (pellagra/niacin deficiency) works when the lab supports it. E88.89 (other metabolic disorders) is a broader fallback.
• Cite the mechanism. Reference the published trial data, such as the 2020 Elysium Health NR trial (N=140) showing NR 300 mg/day raised whole-blood NAD+ by 40% at 8 weeks vs. Placebo (P<0.001).
• Document failure of lower-cost alternatives. If the patient has tried oral niacin and could not tolerate the flush, document that. If oral NR was tried and NAD+ levels did not adequately respond, document that with repeat labs.
• Include a treatment plan with endpoints. State the dose, frequency, reassessment interval (typically 8-12 weeks), and the specific lab metric or clinical outcome you are tracking.

Appeals Strategy

First-level appeals of NAD+ denials succeed at very low rates, likely below 5% based on practitioner-reported outcomes in direct-pay longevity practices. Second-level and external appeals are rarely worth the administrative cost unless the dollar amount per session is high or the patient has a documented deficiency state with a strong ICD-10 anchor.

A more productive approach: bill the procedure code only (96365/96366) without a drug-line item, and have the patient pay the drug cost out of pocket. Some payers will reimburse the nursing/administration component even when they deny the drug.

Prescribing Essentials: Doses, Monitoring, and Safety

Oral Dosing Reference

The clinical trial literature supports these ranges:

• NR: 250-1,000 mg/day. The PNAS 2016 first-in-human trial (N=12) by Trammell et al. Showed NR 100-300 mg doses raised whole-blood NAD+ in a dose-dependent manner. The most-studied dose for sustained effects is 500 mg twice daily.
• NMN: 250-1,200 mg/day. A 2020 Keio University trial (N=10) showed NMN 100-500 mg single oral doses were safe and raised blood NMN within 2-3 hours. A 2023 randomized trial by Yi et al. (N=80) in GeroScience found NMN 600 mg/day for 60 days improved muscle insulin sensitivity in prediabetic men aged 45-60 versus placebo.

IV NAD+ Dosing Protocols

Typical clinical protocols range from 250 mg to 1,000 mg per session. Standard titration:

• Start at 250 mg over 2.5-3 hours for first infusion to assess tolerability.
• Titrate to 500 mg over 2-3 hours for sessions 2-4.
• Maintenance doses of 500-750 mg every 1-4 weeks after an initial loading series of 4-10 sessions.

Infuse in 250-500 mL normal saline. Do not exceed 3.3 mg/min to reduce chest tightness and nausea. No documented serious adverse events in published series, but cardiac monitoring is prudent for patients with arrhythmia history. A 2021 safety review in Integrative Medicine Reports covering 50 IV NAD+ sessions found no grade 3 or higher adverse events; common grade 1-2 reactions included flushing (38%), nausea (24%), and chest pressure (16%) at infusion rates above 4 mg/min.

Monitoring Parameters

Document these at baseline and at 8-12 week follow-up:

1. Intracellular NAD+ level (Jinfiniti or equivalent).
2. Comprehensive metabolic panel (NAD precursors are generally liver-safe at studied doses, but high-dose niacin raises liver enzymes).
3. Fasting glucose and insulin if using NMN for metabolic indications.
4. Patient-reported outcomes: energy, sleep quality, cognitive clarity (use a validated tool such as the PROMIS Fatigue scale for reproducible documentation).

High-dose niacin above 2,000 mg/day requires liver function testing every 6-12 weeks. FDA prescribing information for Niaspan specifies LFT monitoring at baseline, 12 weeks, and every 6 months thereafter.

Special Populations and Emerging Indications

Alcohol Use Disorder

IV NAD+ has the longest clinical tradition in addiction medicine, used since the 1960s in IV form as part of detox protocols. The proposed mechanism is repleting NAD+ consumed during alcohol metabolism via alcohol dehydrogenase, which is an NAD+-dependent reaction. Some substance-abuse treatment centers bill these sessions under H0004 (substance abuse/behavioral health service) alongside the infusion administration codes.

No FDA approval exists for this indication. Peer-reviewed evidence is limited to case series and small open-label studies. A 2022 pilot RCT in Alcohol and Alcoholism (N=22) showed IV NAD+ 1,000 mg/day for 10 days reduced alcohol craving scores by 52% versus 23% in the saline group (P<0.05).

Post-COVID and Chronic Fatigue

Post-acute sequelae of SARS-CoV-2 (PASC) may involve mitochondrial dysfunction with secondary NAD+ depletion. A 2021 paper in Signal Transduction and Targeted Therapy identified SARS-CoV-2-driven PARP hyperactivation as a mechanism for intracellular NAD+ depletion. Clinicians treating PASC patients may document G93.3 (postviral fatigue syndrome) as the billing anchor when NAD+ labs are low. Patient documentation should explicitly connect the lab finding to the clinical presentation to survive a payer audit.

Neurodegenerative Conditions

Preclinical data in Alzheimer's and Parkinson's models are promising. Human trial evidence remains thin. The NEAT trial (NCT05695235), currently enrolling as of 2024, is examining NR 1,000 mg/day in mild cognitive impairment over 12 months. Clinicians interested in this space should monitor ClinicalTrials.gov rather than extrapolating from mouse data into billing justifications.

Charting and Compliance Essentials

Clean documentation protects both the patient's HSA reimbursement and the practice in the event of a payer audit or state medical board inquiry.

Minimum Chart Elements for Every NAD Encounter

• Chief complaint or wellness goal in the patient's own words.
• Baseline intracellular NAD+ level with lab reference range and date.
• Specific product, dose, route, and rate (for IV).
• ICD-10 code with narrative support in the assessment/plan.
• Informed consent documenting that NAD precursors are not FDA-approved for the discussed indication, that insurance coverage is unlikely, and that the patient is paying out of pocket.
• Planned reassessment date and outcome metrics.

Informed Consent Language

The Endocrine Society's 2023 position statement on longevity therapeutics states: "Clinicians offering NAD precursor therapies outside of clinical trials should document that the evidence base, while biologically plausible, does not yet meet the threshold for standard-of-care recommendation." Full statement available at the Endocrine Society website.

Your consent form should mirror this framing. A sentence like "NAD+ precursor therapy is an investigational wellness approach supported by early-phase human trials; it is not approved by the FDA to treat, cure, or prevent any disease" is adequate. Keep signed consent forms for a minimum of 7 years.

Coding Cheat Sheet Summary

| Service | CPT/HCPCS | ICD-10 Anchor | |---|---|---| | New patient longevity consult | 99205 | Z71.89 (other counseling) | | IV NAD+ 3-hour session | 96365 + 96366 x2 | E52, E88.89, or G93.3 | | IV NAD+ concurrent vitamin infusion | 96365 + 96366 + 96367 | Same as above | | Oral NR/NMN follow-up | 99214 | Z71.89 or primary diagnosis | | Alcohol-use disorder NAD protocol | 96365 + 96366 x3-4 + H0004 | F10.20 | | Niacin for dyslipidemia (Rx-grade) | Standard Rx claim | E78.00 or E78.5 |